A 68-year-old man develops acute hepatocellular injury during treatment with direct-acting antiviral agents (DAA) for hepatitis C. Medical history reveals the intake of tamoxifen as adjuvant treatment for breast cancer, currently in remission. After stopping tamoxifen, despite the continuation of the anti-HCV agents, a complete resolution of liver injury occurs. This interesting case illustrates tamoxifen hepatotoxicity induced by CYP3A4 interaction with direct anti-HCV agents. It stresses the importance of checking for interactions before starting treatment for hepatitis C.
RibeiroMPCSantosAECustodioJBA. Mitochondria: the gateway of tamoxifen-induced liver injury. Toxicology2014; 323: 10–18.
2.
AntunesMVda Fontoura TimmTAde OliveiraV, et al.Influence on CYP2D6 and CYP3A4 phenotypes, drug interactions, and vitamin D status on tamoxifen biotransformation. Ther Drug Monit2015; 37: 733–744.
3.
Hansten PD. The underrated risk of tamoxifen drug interactions. Eur J Drug Metab Pharmacokinet 2018; 43(5): 495–508.
SaphnerTTriest-RobertsonSLiH, et al.The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer2009; 115: 3189–3195.
6.
PanHJChangHTLeeCH. Association between tamoxifen treatment and the development of different stages of nonalcoholic fatty liver disease among breast cancer patients. J Formos Med Assoc2016; 115: 4211–4417.
7.
LiuCLHuangJKChengSP, et al.Fatty liver and transaminase changes with adjuvant tamoxifen therapy. Anticancer Drugs2006; 17: 709–713.
8.
BlackburnAMAmielSAMillisRR, et al.Tamoxifen and liver damage. Br Med J1984; 289: 288–288.
9.
ChingCKSmithPGLongRG. Tamoxifen-associated hepatocellular damage and agranulocytosis. Lancet1992; 339: 940–940.
10.
OienKAMoffatDCurryGW, et al.Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet1999; 353: 36–37.
KlibanovOMGaleSESantevecchiB. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. Ann Pharmacother2015; 49: 566–581.
13.
MenonRMBadriPSWangT, et al.Drug-drug interaction profile of the all-oral antihepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol2015; 63: 20–29.
